To include your compound in the COVID-19 Resource Center, submit it here.

Allosteric inhibitor of PGAM1 identified for NSCLC

DISEASE CATEGORY: Cancer

INDICATION: Non-small cell lung cancer (NSCLC)

A benzenesulfonamide-based allosteric inhibitor of PGAM1, given alone or in combination with the EGFR inhibitor Tarceva erlotinib,

Read the full 244 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE